IQVIA brings you specialized expertise in successful early phase design strategies and delivery—bolstered by more than 15 Therapeutic and Specialty Centers of Excellence across a breadth of medical domains.

Let IQVIA help you customize your adaptive-design protocol to accelerate delivery — and ensure safety and quality — even in the most complex studies and populations.

Diverse, therapeutically aligned sites across 80 countries — including critical geographical regions. Work with IQVIA’s in-house site in the UK, selective network of trusted partner sites, and 3rd party sites.

Expedite molecule advancement with IQVIA’s integrated phase I-IIa delivery model that retains institutional knowledge and maximizes efficiency and continuity — with one SOP, one platform and one project manager.

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.

Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.

Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.